DOP49 Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group

Background Vedolizumab is the first biologic tested for the treatment of elderly patients with moderate-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD) in the GEMINI program. However, little real-life data have been reported on its use in the elderly population. In this work, we present data on vedolizumab effectiveness and safety in a large cohort of elderly UC and CD patients matched to younger patients. Methods The...